Ocean Genomics and Geneyx to Enrich Genomic Variant Detection to Better Diagnose Diseases and Identify Drug Targets
Summary
This joint effort aims to combine DNA and RNA technologies, revolutionizing the detection of genomic variants and significantly advancing disease diagnosis and drug target identification.Improved identification of structural variants in cancer can lead to more targeted and effective treatment options as well as advance our basic understanding of the disease and its progression. Integrating DNA and RNA technologies to create a multi-omic software method holds tremendous potential for improving disease diagnosis and identifying drug targets. Their innovative multi-omic software technique has the potential to revolutionize the field of genomics and significantly contribute to the diagnosis of diseases and identification of drug targets. It provides grants and funding opportunities to support joint research and development projects, fostering technological advancements and business partnerships. With a focus on promoting cross-border cooperation, the BIRD Foundation plays a crucial role in driving economic growth and knowledge exchange between Israel and the United States.Media Contacts:Anja Taylor, Director of Marketing, Ocean Genomicsanja@oceangenomics.comRaviv Itzhaky, CMO, GeneyxHq@geneyx.com
Classifications
AskAI Classifications
LabelsLinked Companies
